Khursheed Aurangzeb

57194517674

Publications - 2

Global, regional, and national burden of chronic kidney disease in adults, 1990–2023, and its attributable risk factors: a systematic analysis for the Global Burden of Disease Study 2023

Mohamad Amin Bakhshali Shoshana H. Ballew Ovidiu Constantin Baltatu Maciej Banach Mainak Bardhan Ahmed Abdelrahman Abdelgalil Saurav Basu Bekalu Mekonen Belay Makda Abate Belew Aminu K. Bello Luis Belo Amiel Nazer C. Bermudez Fahmi Y. Al-Ashwal Nurudeen A. Adegoke Nelson Alvis-Guzman Yaser Mohammed Al-Worafi Adel Sharaf Al-Zubairi Masoud Aman Mohammadi Hubert Amu Filippos Anagnostakis Abhishek Anil Sajjad Ahmad Neeraj Bedi Anayochukwu Edward Anyasodor Geminn Louis Carace Apostol Walter Appati Sulaimon O. Araromi Hiba Jawdat Barqawi Rizwan Suliankatchi Abdulkader Amir Mahmoud Ahmadzade Salah Al Awaidy Syed Shujait Ali Omar Almidani Hanadi Al Hamad Syed Mahfuz Al Hasan Karem H. Alzoubi Maha Moh'd Wahbi Atout Samar Abd ElHafeez Sajjad Ahmad Nesredin Ahmed Marjan Ajami Ayman Ahmed Yazan Al Thaher Salahdein Aburuz Ashagre Molla Assaye Khursheed Aurangzeb Adedapo Wasiu Awotidebe Domenico Azzolino Muhammad Badar Lucas Guimarães Abreu Qorinah Estiningtyas Sakilah Adnani Bright Opoku Ahinkorah Dmitry Abramov Bilyaminu Abubakar Olugbenga Olusola Abiodun Oyelola A. Adegboye Isaac Yeboah Addo Qorinah Estiningtyas Sakilah Adnani Hasan Aalruz Qorinah Estiningtyas Sakilah Adnani M. D.Abu Bashar Shahid Bashir Mohammad Mahdi Bastan Akshaya Srikanth Bhagavathula Sonu Bhaskar Ajay Nagesh Bhat Temitayo Esther Adeyeoluwa Johan Ärnlöv Bernard Kwadwo Yeboah Asiamah-Asare Syed Anees Ahmed Patrick B. Mark Lauryn K. Stafford Morgan E. Grams Hansani Madushika Abeywickrama Mohammed Mehdi Abrar Khabir Ahmad Hasan Aalruz Ali Ahmadi Aram Mahmood Ahmed Shahzaib Ahmed Priyadarshini Bhattacharjee Jasvinder Singh Bhatti Salahdein Aburuz Aleksandr Y. Aravkin Mohammed Z. Allouh Mohammadreza Akbari Oluwasefunmi Akeju Mohammed Ahmed Akkaif Ziyad Al-Aly Mohammed Albashtawy Shereen M. Aleidi Ali M. Alfalki Fadwa Naji Alhalaiqa Khalid A. Alhasan Endale Alemayehu Ali Rafat Ali Syed Yusuf Ali Samah W. Al-Jabi Mohammed Z. Allouh Wesam Taher Almagharbeh Maha Moh d.Wahbi Atout Khaldoon Aied Alnawafleh Najim Z. Alshahrani Awais Altaf Sadat Abdulla Aziz Jesu Arockiaraj Yuni Asri Sadat Abdulla Aziz Rizwan Suliankatchi Abdulkader

Publication Name: Lancet

Publication Date: 2025-11-22

Volume: 406

Issue: 10518

Page Range: 2461-2482

Description:

Background Chronic kidney disease (CKD) is common and ranks among the leading causes of mortality and morbidity. This analysis aimed to present global CKD estimates using the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2023 to inform evidence-based policies for CKD identification and treatment. Methods This analysis focused on adults aged 20 years and older over the period 1990 to 2023, from 204 countries and territories. Data sources used were published literature, vital registration systems, kidney failure treatment registries, and household surveys. Estimates of CKD burden, including deaths, incidence, prevalence, and disability-adjusted life-years (DALYs), were produced using a Cause of Death Ensemble model and a Bayesian meta-regression analytical tool. A comparative risk assessment approach estimated the proportion of cardiovascular deaths attributable to impaired kidney function and estimated risk factors for CKD. Findings Globally, in 2023, 788 million (95% uncertainty interval 743–843) people aged 20 years and older were estimated to have CKD, up from 378 million (354–407) in 1990. The global age-standardised prevalence of CKD in adults was 14·2% (13·4–15·2), a relative rise of 3·5% (2·7–4·1) from 1990. The region with the highest age-standardised prevalence was north Africa and the Middle East (18·0%; 16·9–19·4). Most people had stage 1–3 CKD, with a combined prevalence of 13·9% (13·1–15·0). In 2023, CKD was the ninth leading cause of death globally, accounting for 1·48 million (1·30–1·65) deaths, and the 12th leading cause of DALYs, with an age-standardised DALY rate of 769·2 (691·8–857·4) per 100 000. Impaired kidney function as a risk factor accounted for 11·5% (8·4–14·5) of cardiovascular deaths. High fasting plasma glucose, body-mass index, and systolic blood pressure were all leading risk factors for CKD DALYs. Interpretation CKD is a major global health issue, with rising prevalence and increasing importance as a cause of death and as a risk factor for cardiovascular death. A better understating of aetiology, appropriate screening, and implementation programmes are needed to translate advances in CKD treatment into improved patient outcomes. Funding Gates Foundation, Wellcome, US National Kidney Foundation, and US National Institute of Diabetes and Digestive and Kidney Diseases.

Open Access: Yes

DOI: 10.1016/S0140-6736(25)01853-7

Global, regional, and national burden of headache disorders, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023

Sharareh Eskandarieh Andre Faro Giuseppina Affinito Yaser Mohammed Al-Worafi Abhishek Anil Mohammad Amin Aalipour Hiba Jawdat Barqawi Dariush Abtahi Danish Ahmad Jalal Arabloo Syed Shujait Ali Karem H. Alzoubi Yasser Bustanji Salahdein Aburuz Khursheed Aurangzeb Qorinah Estiningtyas Sakilah Adnani Deldar Morad Abdulah Qorinah Estiningtyas Sakilah Adnani Richard Gyan Aboagye Mohammad Mahdi Bastan Sonu Bhaskar Mohammad Al-Wardat Ganiyu Adeniyi Amusa Demelash Areda Mahsa Asadi Anar Sait Ashina Joseph Uy Almazan Negar Sadat Ahmadi Mohammad Ahmmad Mahmoud Al Zoubi Mohammed Usman Ali Andreas Kattem Husøy Yvonne Yiru Xu Jaimie D. Steinmetz Samir Abu Rumeileh Obed Adonteng-Kissi Ali Ahmed Sawsan Alabbad Yazan Al-Ajlouni Ashraf Alhumaidi Gelana Fekadu Hasan Aalruz Shahzaib Ahmed Jasvinder Singh Bhatti Luis Alberto Cámera C. J. Sanjay Natalia Cruz-Martins Edoardo Caronna Ana Paula Carvalho-E-Silva Jeetendra Bhandari Patrick R. Ching Hongyuan Chu Josielli Comachio Bijit Biswas Arian Azadnia Aleksandr Y. Aravkin Youngoh Bae Sandip Chakraborty Rehana Basri Jina Behjati Mohammad Asghari-Jafarabadi Daniela Contreras Omid Dadras Gurjit Kaur Bhatti Rajbir Bhatti Emanuele D'Amico Anh Kim Dang Lucio D'Anna Bruno Bizzozero-Peroni Archith Boloor Meriem Boukhiam Sindhura Deekonda Pouria Delbari Andreas K. Demetriades Emina Dervišević Lamiaa Labieb Mahmoud Ebraheim Ebrahim Eini Michael Ekholuenetale Vijay Kumar Chattu Razieh Bahreini Maryam Bemanalizadeh Anis Ahmad Chaudhary Xiaochen Dai Vinoth Gnana Chellaiyan Devanbu Amol S. Dhane Bibha Dhungel Joseph Uy Almazan Sohrab Amiri Montaha Al-Iede David B. Anderson Mohammed Albashtawy Fadwa Naji Alhalaiqa Asma Ahmed Ahmed Y. Azzam Soham Bandyopadhyay C. J. Sanjay Natalia Cruz-Martins Valery L. Feigin Azadeh Bashiri Najim Z. Alshahrani Awais Altaf Xueting Ding Huyen Phuc Do Ojas Prakashbhai Doshi Siddhartha Dutta

Publication Name: Lancet Neurology

Publication Date: 2025-12-01

Volume: 24

Issue: 12

Page Range: 1005-1015

Description:

Background: The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2023 estimates health loss from migraine, tension-type headache, and medication-overuse headache. This study presents updated results on headache-attributed burden from 1990 to 2023, along with clinical and public health implications. Methods: Data on the prevalence, incidence, or remission of migraine, tension-type headache, and medication-overuse headache were extracted from published population-based studies. We used hierarchical Bayesian meta-regression modelling to estimate global, regional, and country-level prevalence of headache disorders. For the first time in GBD 2023, age-specific and sex-specific estimates of time in symptomatic state were applied by meta-analysing individual participant data from 41 653 individuals from the general populations of 18 countries from all parts of the world. Disability weights were applied to calculate years lived with disability (YLDs). Since medication-overuse headache is a sequela of a mistreated primary headache (due to medication overuse), its burden was reattributed to migraine or tension-type headache, informed by a meta-analysis of three longitudinal studies. Findings: In 2023, 2·9 billion individuals (95% uncertainty interval 2·6–3·1) were affected by headache disorders, with a global age-standardised prevalence of 34·6% (31·6–37·5) and a YLD rate of 541·9 (373·4–739·9) per 100 000 population, with 487·5 (323·0–678·8) per 100 000 population attributed to migraine. The prevalence rates of these headache disorders have remained stable over the past three decades. YLD rates due to headache disorders were more than twice as high in females (739·9 [511·2–1011·5] per 100 000) as in males (346·1 [240·4–481·8] per 100 000). Medication-overuse headache contributed 58·9% of the YLD estimates for tension-type headache in males and 56·1% in females, as well as 22·6% of the YLD estimates for migraines in males and 14·1% in females. Interpretation: Headache disorders, in particular migraine, continue to be a major global health challenge, emphasising the need for effective management and prevention strategies. Much headache-attributed burden could be averted or eliminated by avoiding overuse of medication (including over-the-counter medication), underscoring the importance of public education. Funding: Gates Foundation.

Open Access: Yes

DOI: 10.1016/S1474-4422(25)00402-8